Literature DB >> 16377959

Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety.

Mariusz Papp1, Ewa Litwa, Piotr Gruca, Elisabeth Mocaër.   

Abstract

The activity of the novel antidepressant agomelatine was evaluated in three models of anxiety and compared with that of melatonin and two anxiolytics, diazepam and buspirone. All drugs were tested 2 h before and 2 h after the dark phase of the diurnal cycle. Morning and evening agomelatine (10-75 mg/kg) administration increased animals' responses in the elevated plus maze and Vogel tests. Melatonin (10-75 mg/kg) enhanced open arms exploration in the evening experiment and was inactive in the Vogel test. In the conditioned ultrasonic vocalization test, agomelatine, but not melatonin, was active in the morning and evening experiment. Melatonin antagonist, S22153 (20 mg/kg), enhanced the action of morning and evening agomelatine administration in the Vogel and conditioned ultrasonic vocalization tests, while in the elevated plus maze test, S22153 inhibited effects of evening but not morning melatonin and agomelatine administration. These results indicate the involvement of both the melatonin and the 5-HT2C receptors in the mechanism of anxiolytic-like action of agomelatine.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16377959     DOI: 10.1097/01.fbp.0000181601.72535.9d

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  30 in total

1.  Ozone exposure of Flinders Sensitive Line rats is a rodent translational model of neurobiological oxidative stress with relevance for depression and antidepressant response.

Authors:  Mmalebuso L Mokoena; Brian H Harvey; Francois Viljoen; Susanna M Ellis; Christiaan B Brink
Journal:  Psychopharmacology (Berl)       Date:  2015-04-17       Impact factor: 4.530

2.  Assessing the Dim Light Melatonin Onset in Adults with Autism Spectrum Disorder and No Comorbid Intellectual Disability.

Authors:  Emma K Baker; Amanda L Richdale; Agnes Hazi; Luke A Prendergast
Journal:  J Autism Dev Disord       Date:  2017-07

Review 3.  The Black Book of Psychotropic Dosing and Monitoring.

Authors:  Alan F Schatzberg; DeBattista Charles
Journal:  Psychopharmacol Bull       Date:  2018-01-15

4.  Antidepressant- and anxiolytic effects of the novel melatonin agonist Neu-P11 in rodent models.

Authors:  Shao-wen Tian; Moshe Laudon; Li Han; Jun Gao; Fu-lian Huang; Yu-feng Yang; Hai-feng Deng
Journal:  Acta Pharmacol Sin       Date:  2010-06-28       Impact factor: 6.150

5.  S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models.

Authors:  Anne Dekeyne; Clotilde Mannoury la Cour; Alain Gobert; Mauricette Brocco; Françoise Lejeune; Florence Serres; Trevor Sharp; Annie Daszuta; Amélie Soumier; Mariusz Papp; Jean-Michel Rivet; Gunnar Flik; Thomas I Cremers; Olivier Muller; Gilbert Lavielle; Mark J Millan
Journal:  Psychopharmacology (Berl)       Date:  2008-06-04       Impact factor: 4.530

Review 6.  Unveiling the role of melatonin MT2 receptors in sleep, anxiety and other neuropsychiatric diseases: a novel target in psychopharmacology.

Authors:  Stefano Comai; Gabriella Gobbi
Journal:  J Psychiatry Neurosci       Date:  2014-01       Impact factor: 6.186

Review 7.  Agomelatine, the first melatonergic antidepressant: discovery, characterization and development.

Authors:  Christian de Bodinat; Béatrice Guardiola-Lemaitre; Elisabeth Mocaër; Pierre Renard; Carmen Muñoz; Mark J Millan
Journal:  Nat Rev Drug Discov       Date:  2010-06-25       Impact factor: 84.694

8.  Agomelatine (S20098) modulates the expression of cytoskeletal microtubular proteins, synaptic markers and BDNF in the rat hippocampus, amygdala and PFC.

Authors:  Nataly Ladurelle; Cecilia Gabriel; Adela Viggiano; Elisabeth Mocaër; Etienne E Baulieu; Massimiliano Bianchi
Journal:  Psychopharmacology (Berl)       Date:  2011-12-08       Impact factor: 4.530

Review 9.  Agomelatine: a preliminary review of a new antidepressant.

Authors:  Michael Zupancic; Christian Guilleminault
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

10.  Disturbances of diurnal phase markers, behavior, and clock genes in a rat model of depression; modulatory effects of agomelatine treatment.

Authors:  K Højgaard; S L Christiansen; E V Bouzinova; O Wiborg
Journal:  Psychopharmacology (Berl)       Date:  2017-11-19       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.